XTL Biopharmaceuticals Ltd. Statistics
Share Statistics
XTL Biopharmaceuticals Ltd. has 11.59M shares outstanding. The number of shares has increased by 130.19% in one year.
| Shares Outstanding | 11.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 163.2% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 11.56M |
| Failed to Deliver (FTD) Shares | 160 |
| FTD / Avg. Volume | 0.38% |
Short Selling Information
The latest short interest is 8.56K, so 0.07% of the outstanding shares have been sold short.
| Short Interest | 8.56K |
| Short % of Shares Out | 0.07% |
| Short % of Float | 0.07% |
| Short Ratio (days to cover) | 2.39 |
Valuation Ratios
The PE ratio is -2860.68 and the forward PE ratio is null.
| PE Ratio | -2860.68 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 2.3 |
| P/FCF Ratio | -7.21 |
| PEG Ratio | n/a |
Enterprise Valuation
XTL Biopharmaceuticals Ltd. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 9.93, with a Debt / Equity ratio of 0.
| Current Ratio | 9.93 |
| Quick Ratio | 10.07 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is -34.46%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | -34.46% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -222.75K |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 94.68% in the last 52 weeks. The beta is 1, so XTL Biopharmaceuticals Ltd.'s price volatility has been higher than the market average.
| Beta | 1 |
| 52-Week Price Change | 94.68% |
| 50-Day Moving Average | 1.92 |
| 200-Day Moving Average | 2.3 |
| Relative Strength Index (RSI) | 46.47 |
| Average Volume (20 Days) | 42.04K |
Income Statement
In the last 12 months, XTL Biopharmaceuticals Ltd. had revenue of $0 and earned -$1.78M in profits. Earnings per share was $0.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -765.00K |
| Net Income | -1.78M |
| EBITDA | -764.00K |
| EBIT | - |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has $1.40M in cash and $0 in debt, giving a net cash position of $1.40M.
| Cash & Cash Equivalents | 1.40M |
| Total Debt | 0 |
| Net Cash | 1.40M |
| Retained Earnings | -158.25M |
| Total Assets | 2.93M |
| Working Capital | 2.33M |
Cash Flow
In the last 12 months, operating cash flow was -$707.00K and capital expenditures $0, giving a free cash flow of -$707.00K.
| Operating Cash Flow | -707.00K |
| Capital Expenditures | 0 |
| Free Cash Flow | -707.00K |
| FCF Per Share | 0 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
XTLB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0% |
| FCF Yield | -3.33% |
Analyst Forecast
Currently there are no analyst rating for XTLB.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Feb 10, 2017. It was a backward split with a ratio of 1:5.
| Last Split Date | Feb 10, 2017 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | -17.83 |
| Piotroski F-Score | 2 |